The Pharma Data

DECEMBER 29, 2020

Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

Life Science 52

Life Science Bioavailability Clinical Trials Clinical Trials 52

pharmaphorum

NOVEMBER 9, 2022

for the purpose of advancing disease-modifying oral medicines for debilitating chronic neurodegenerative disorders, by enabling investigational new drugs (IND) studies. A pre-clinical pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability pore (mPTP) are to be developed.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

Drug Discovery World

JULY 25, 2023

The guidance is for pharmaceutical companies conducting paediatric clinical trials in the EU using the PIP procedure. PIPs are mandatory for applicants seeking marketing authorisation for new medicines in the EU. They are required for orphan drugs but not for biosimilars.

Development 52

Development Drugs Medicine Production 52

Camargo

JULY 8, 2021

Researchers at the Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have observed that MAOIs might help the immune system attack cancer. Although still available as generics, for the most part they have been replaced by newer drugs with fewer side effects.

Development 130

Development Bioequivalency Gene Expression Drugs 130

The Pharma Data

NOVEMBER 26, 2020

This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. Nanoform is an innovative nanoparticle medicine enabling company. HELSINKI , Nov.

Containment 52

Containment Medicine Bioavailability Clinical Trials 52

The Pharma Data

AUGUST 16, 2021

Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Week 16 in two pivotal Phase 3 trials in lebrikizumab clinical trial program – Safety profile consistent with prior lebrikizumab studies in atopic dermatitis. 1-4 The U.S. About Lilly in Dermatology.

Dermatology 40

Dermatology Trials Bioavailability Medicine 40

The Pharma Data

JANUARY 3, 2021

4, 2021 /PRNewswire/ — Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced a new near-term business target. Nanoform is an innovative nanoparticle medicine enabling company. HELSINKI , Jan.

Containment 52

Containment Bioavailability Clinical Trials Clinical Trials 52

The Pharma Data

MARCH 11, 2021

Last May, Lilly’s first-in-class oral precision medicine, Retevmo received Accelerated Approval from the U.S. Lilly will present findings from a post-hoc safety analysis of the Phase 1/2 LIBRETTO-001 trial, the largest clinical trial in patients with RET -altered cancers. Session Title: Phase II Clinical Trials.

Research 52

Research Clinical Trials Clinical Trials Trials 52

Roots Analysis

SEPTEMBER 1, 2023

By using real-world evidence , researchers can gain clinically useful insights that can help improve the quality of care delivery in precision medicine. As the field continues to advance, it is expected to have a profound impact on the future of medicine.

Drug Delivery 52

Drug Delivery Marketing Drug Delivery Systems Drugs 52

The Pharma Data

NOVEMBER 22, 2020

Founded in 2007, Alzprotect is a French Lille-based company created by Dr. André Delacourte, one of the pioneers of research on Alzheimer’s disease, and Dr. Patricia Melnyk, expert in medicinal chemistry, in collaboration with University of Lille and Inserm. About XERYS.

Drugs 40

Drugs Protein Bioavailability Development 40

The Pharma Data

DECEMBER 1, 2020

The SDS is a patient-rated scale that was designed to assess functioning in work, social life, and family life, and is among the most commonly used functional impairment scales in depression clinical trials. Clinical response on the SDS (defined as a total score of ?12) 12) after treatment with AXS-05 was achieved by 37.1%

Trials 52

Trials Clinical Trials Clinical Trials Production 52

The Pharma Data

DECEMBER 8, 2020

Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 8,110,000 shares of its common stock at a price to the public of $37.00 SAN DIEGO, Dec. About Kura Oncology.

Bioavailability 52

Bioavailability Containment Sales Medicine 52

The Pharma Data

NOVEMBER 19, 2020

These compounds have demonstrated high potency in inhibiting the activity of the M pro protease as well as promising oral bioavailability and blood plasma levels in animal studies. Several compounds are being further optimized for preclinical studies. Details can be found at this link.

Development 40

Development Bioavailability Production Drugs 40

The Pharma Data

DECEMBER 3, 2020

Food and Drug Administration and European Medicines Agency as we work to bring maribavir to patients.”. Maribavir, an orally bioavailable anti-CMV compound, is the only antiviral agent presently in Phase 3 development for the treatment of post-transplant patients with CMV in SOT or HSCT. 4, 2020 11:00 UTC. About Maribavir.

Drugs 52

Drugs Medicine Trials Containment 52

Delveinsight

JULY 30, 2020

Another player in the race to advance ALD market size is Minoryx Therapeutics who recently announced the beginning of the registration-enabling Phase 2 NEXUS trial to evaluate the safety and efficacy of leriglitazone in pediatric patients with early-stage cerebral ALD (cALD), the acute form of X-linked adrenoleukodystrophy (X-ALD).

Hormones 52

Hormones Marketing Gene Trials 52

Pharmaceutical Technology

NOVEMBER 24, 2022

The ADME study results form an important part of the Investigational New Drug (IND) approval process in the US and for the submission of a national Clinical Trial Authorization (CTA) in the EU. How does your unique Synthesis-to-Clinic® offering streamline the drug development process?

Bioavailability 130

Bioavailability Manufacturing Drugs Production 130

Pharmaceutical Technology

FEBRUARY 13, 2023

By associating molecular properties with in-silico absorption, distribution, metabolism, excretion, and toxicity (ADMET) models, we can significantly increase the robustness of candidate selection, which subsequently reduces the failure rate during clinical trials.

Development 130

Development In-Vivo Clinical Trials Clinical Trials 130

Drug Discovery World

JANUARY 24, 2024

Can you elaborate on the clinical timeline for these small molecules? Fibrocor is on track to complete all IND-enabling work to support IND filing and initiation of clinical trials in 2024. He has been responsible for all aspects of drug discovery, preclinical research, CM&C, Phase I and Phase II clinical trials.

Research 59

Research Gene Expression Drugs Development 59

XTalks

AUGUST 30, 2022

The webinar also featured Kelsey Carter, MS, Clinical Trial Manager at Medpace who discussed the site, operational and regulatory challenges for neuroscience trials with direct CNS administration along with the strategies to mitigate these challenges. Targeting the CNS directly has been successful in modern medicine.

Trials 83

Trials Drug Delivery Drugs Gene 83

Pharmaceutical Technology

AUGUST 3, 2022

If clinical trials prove successful, that same process should then be scaled to commercial manufacturing. Today, they are still thought to represent approximately two-thirds of all medicines administered through prescription and over-the-counter.

Development 130

Development Production Manufacturing Bioavailability 130

Drug Discovery World

FEBRUARY 2, 2023

ends a federal mandate that experimental drugs need to be tested on animals before they can be used in human clinical trials 2. As reported by DDW , the system will initially be investigated for improving the preclinical estimation of human drug bioavailability compared to standard animal models.

Drugs 52

Drugs Clinical Trials Clinical Trials Cosmetics 52

Delveinsight

SEPTEMBER 8, 2021

The risk factors for SLE include the medicines that induce lupus, age, race/ethnicity, and family history. It is also available as a generic medicine. There are several SLE therapies in the pipeline that are under investigation in different phases of clinical trials for the treatment of Systemic Lupus Erythematosus.

Marketing 52

Marketing Sales FDA Approval Antibody 52

Drug Discovery World

APRIL 17, 2023

New bispecific antibody study results for multiple myeloma According to results of a phase I/II clinical trial presented today, patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% Read more here.

Research 52

Research Antibody Bioavailability Genetics 52